DrugMonitor™ Anti-Plozalizumab Antibody (VS-1224-YC931) (CAT#: VS-1224-YC931)
Plozalizumab has been researched for treating atherosclerosis as a humanized monoclonal antibody specifically targeting CCR2. The DrugMonitor™ Anti-Plozalizumab Antibody (VS-1224-YC931) is an anti-drug antibody (ADA) against Plozalizumab. This drug-based antibody is raised in mice immunized with the Plozalizumab. The anti-Plozalizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Plozalizumab in samples.
Specific Inquiry
Specifications
- Host Animal
- Mouse
- Specificity
- Plozalizumab
- Target
- Plozalizumab
- Immunogen
- Plozalizumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Plozalizumab
- Related Disease
- Atherosclerosis
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Plozalizumab"
Anti-Human CCR2 Recombinant Antibody (Plozalizumab)Recombinant monoclonal antibody to CCR2. Plozalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Atherosclerosis, Diabetic nephropathies, Malignant melanoma. It binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2.
Afuco™ Anti-CCR2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-444CQ)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CCR2. It is a humanized monoclonal antibody that can be potentially used in the treatment of Atherosclerosis, Diabetic nephropathies, Malignant melanoma. It binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-1224-YC931. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: FC, IHC, FuncS, Inhib, Cyt
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
-YJ1.png)
Application: WB, ELISA, FC, IHC, IP
Application: ELISA
Application: Neut, ELISA, WB, SPR, IF, EM
Application: ELISA, IHC, WB
Application: ELISA, IHC, IF, IP
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
